Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Stock Is Sinking Again Today

By Keith Speights - May 11, 2021 at 12:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of its senior convertible notes offering.

What happened

Shares of Dynavax Technologies (DVAX 4.75%) were trading 5.4% lower as of 11:22 a.m. EDT on Tuesday. The decline came after the company announced the pricing of a $200 million offering of senior convertible notes. Dynavax stock also nosedived on Monday following the company's announcement of plans for the debt offering.

So what

Dynavax stated that the conversion price of the notes will be the equivalent of around $10.47 per share. This represents a 32.5% premium over the closing price of the biotech stock on Monday.

Two hands holding letters spelling "Debt"

Image source: Getty Images.

In its initial announcement about the debt offering on Monday, the company explained that it plans to use the proceeds to pay off debt and purchase capped calls. These capped calls will give Dynavax call options to buy its shares and offset the potential dilution to the value of existing shares.

Dynavax provided additional details Tuesday morning. The biotech said that it expects to raise around $195.1 million in net proceeds from the notes offering. That total will rise to $224.4 million if the initial purchasers exercise their options to buy the full allotment of additional notes. Dynavax plans to use around $190.2 million of that sum to repay its debt under the company's term loan agreement. Around $24.2 million will be used to fund the capped call transactions.

Now what

The main things investors should watch for regarding Dynavax are results from clinical studies conducted by its partners that are using its CpG 1018 adjuvant to enhance the effectiveness of their vaccines. Dynavax expects that adjuvant will be a key growth driver throughout 2021 and beyond.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$17.44 (4.75%) $0.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.